Novartis AG (NVSEF) Stock

About Novartis AG

Novartis AG, a global pharmaceutical enterprise established in 1996 and based in Basel, Switzerland, is engaged in the entire lifecycle of healthcare products, from research and development to manufacturing and worldwide commercialization. The company's operations are divided into two main divisions: Innovative Medicines and Sandoz. The Innovative Medicines segment is dedicated to providing advanced prescription medications to both patients and healthcare professionals. Its extensive product portfolio covers a wide range of therapeutic areas, including ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory conditions, cardiovascular health, renal diseases, and metabolism. Conversely, the Sandoz segment specializes in a comprehensive array of generic and biosimilar products. This involves the creation, production, and distribution of finished dosage form medicines, as well as active ingredients and small molecule pharmaceuticals for external partners. Sandoz also supplies generic drugs for retail, anti-infectives, and crucial active pharmaceutical ingredients (APIs) and intermediates, particularly antibiotics. Additionally, this division is involved in developing protein-based and other biotechnology products, such as biosimilars, and offers biotechnology manufacturing services. Novartis AG also pursues strategic collaborations. It has a licensing and collaboration agreement with Alnylam Pharmaceuticals concerning the development, production, and commercialization of inclisiran. Moreover, the company maintains a clinical partnership with Kura Oncology, Inc. to assess the combined efficacy of Tipifarnib and Alpelisib in treating head and neck squamous cell carcinoma patients.

Novartis AG is headquartered in CH.

Novartis AG (NVSEF) stock trades at $151.42 with a market capitalization of $287.81B. The stock is valued at a price-to-earnings (P/E) ratio of 23.73, price-to-book of 7.15, price-to-sales of 5.43. Over the past 52 weeks the stock has ranged between $115.50 and $171.29, and currently trades 11.6% below its 52-week high. It pays a dividend yielding 3.13%.

On profitability, Novartis AG generates a return on equity (ROE) of 29.64% — well above the market average, a sign of a high-quality business, return on capital employed of 18.07%, an operating margin of 29.86%, a net profit margin of 23.09%.

In its most recent fiscal year, Novartis AG reported annual revenue of $57.1B, net profit of $14.6B, revenue has compounded at 2.7% a year over the last five years, profit at 12.7% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 1.18, a current ratio of 0.86, total assets of $115.5B, $11.4B in cash and equivalents.

NVSEF has an average daily trading volume of 23,407 shares, a beta of 0.49 (less volatile than the overall market).

Official website: www.novartis.com